Company Filing History:

13 out of 3,684

Bristol-myers Squibb Compnay

patents

3 out of 183

Universitéde Montreal

patents

where one patent can have more than one assignee

Years Active: 2004-2020

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10822343 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation (2020-11-03),

2. 10428077 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation (2019-10-01),

3. 10047103 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2018-08-14),

4. 7893055 - HIV integrase inhibitors (2011-02-22),

5. 7511037 - N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor (2009-03-31),

6. 7494984 - Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors (2009-02-24),

7. 7192948 - Bicyclic heterocycles as HIV integrase inhibitors (2007-03-20),

8. 7176196 - Bicyclic heterocycles as HIV integrase inhibitors (2007-02-13),

9. 7157447 - Bicyclic heterocycles as HIV integrase inhibitors (2007-01-02),

10. 7109186 - HIV integrase inhibitors (2006-09-19),

11. 6924391 - Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors (2005-08-02),

12. 6890942 - Acyl sulfonamides as inhibitors of HIV integrase (2005-05-10),

13. 6777440 - HIV integrase inhibitors (2004-08-17),

Title: The Innovative Contributions of Roger Remillard

Introduction

Roger Remillard is a notable inventor based in Napierville, CA. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that inhibit platelet aggregation. With a total of 13 patents to his name, Remillard's work has the potential to impact the treatment of thromboembolic disorders.

Latest Patents

One of Remillard's latest patents focuses on imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation. The invention provides thiazole compounds of a specific formula, which can be used as medicaments for treating or preventing thromboembolic disorders. These compounds are designed to inhibit platelet aggregation, showcasing Remillard's commitment to advancing medical treatments.

Career Highlights

Throughout his career, Roger Remillard has worked with prominent organizations such as Bristol-Myers Squibb Company and Université De Montréal. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of Remillard's notable coworkers include Jacques Banville and Michael A. Walker. Their collaborative efforts have further enriched the research landscape in which Remillard operates.

Conclusion

Roger Remillard's innovative work in developing compounds for treating thromboembolic disorders highlights his significant contributions to medicinal chemistry. His patents and collaborations reflect a dedication to improving healthcare through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com